Genomic effects of tamoxifen.
Tamoxifen exerts a variety of genomic effects which explains, in part, its efficacy in both hormone-responsive and independent tumours. The above quotation expresses this in a timeless and elegant way: our understanding of antiestrogen action has been narrowly fettered by the simplistic interpretation of this drug as an antihormone. The regulatory and controlling influence of Tamoxifen on numerous genes involved in apoptosis (p53, Bcl 2, c-myc, erb-B2 and others) will be discussed in this review.
Kellen
J A
JA
Sunnybrook Health Sciences Centre, Department of Clinical Biochemistry, University of Toronto, Ontario, Canada.
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D017209:Apoptosis / Q000235:genetics*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D006133:Growth Substances / Q000378:metabolism; D008565:Membrane Proteins / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D013629:Tamoxifen / Q000494:pharmacology*; D014158:Transcription, Genetic / Q000187:drug effects*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D006133:Growth Substances; D008565:Membrane Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D016159:Tumor Suppressor Protein p53